Exacerbation of Ventilation-Induced Lung Injury and Inflammation in Preterm Lambs by High-Dose Nanoparticles

Ishmael M. Inocencio1, Robert J. Bischof4, Sue D. Xiang3, Valerie A. Zahra2, Vy Nguyen4, Tammy Lim3, Domenic LaRosa3, Jade Barbuto3, Mary Tolcos1,3, Magdalena Plebanski2, Graeme R. Polglase1 & Timothy J. Moss1

Mechanical ventilation of preterm neonates causes lung inflammation and injury, with potential life-long consequences. Inert 50-nm polystyrene nanoparticles (PS50G) reduce allergic inflammation in the lungs of adult mice. We aimed to confirm the anti-inflammatory effects of PS50G in a sheep asthma model, and investigate the effects of prophylactic administration of PS50G on ventilation-induced lung injury (VILI) in preterm lambs. We assessed lung inflammatory cell infiltration, with and without PS50G, after airway allergen challenge in ewes sensitised to house dust mite. Preterm lambs (0.83 gestation) were delivered by caesarean section for immediate tissue collection (n = 5) or ventilation either with (n = 6) or without (n = 5) prophylactic intra-tracheal administration of PS50G nanoparticles (3% in 2 ml). Ventilation was continued for a total of 2 h before tissue collection for histological and biomolecular assessment of lung injury and inflammation. In ewes with experimental asthma, PS50G decreased eosinophilic infiltration of the lungs. Ventilated preterm lambs showed molecular and histological signs of lung injury and inflammation, which were exacerbated in lambs that received PSG50G. PS50G treatment decreased established inflammation in the lungs of asthmatic sheep. However, prophylactic administration of PSG50G exacerbated ventilation-induced lung injury and lung inflammation in preterm lambs.

Preterm birth is the leading cause of neonatal morbidity and mortality1,2, largely as a result of lung disease1. Structural and functional immaturity of the preterm lungs often necessitate respiratory resuscitation and mechanical ventilation4. Unfortunately, up to 85% of preterm infants resuscitated in the delivery room inadvertently receive high tidal volumes5, which can cause lasting lung injury. Studies in lambs show that as few as 6 short, high-volume (Vt, 35 ml/kg) breaths are sufficient to initiate an inflammatory response6,7 that has a persisting effect on the lungs8 and may contribute to chronic lung disease, manifesting as bronchopulmonary dysplasia (BPD).

BPD is a severe lung disease that develops in 20% of infants who receive mechanical ventilation9. It is characterised by the continued requirement for respiratory support for at least 28 days after birth. The pathological features of BPD include simplified alveolar development and abnormal pulmonary vasculature10.

Proinflammatory cytokines (Interleukin (IL) -1β, -6 and -8) and the injury response genes, Early Growth Response Gene 1 (EGR1), Cysteine-Rich 61 (CYR-61), and Connective Tissue Growth Factor (CTGF) are up-regulated in response to ventilation-induced lung injury (VILI)11,12. These mediators likely play integral roles in propagating abnormal lung development. The inflammatory cascade initiated by ventilation-induced lung injury represents a potentially modifiable pathway to BPD. However, to date there has been limited success in prevention or attenuation of lung inflammation resulting from the initiation of ventilation of the preterm lungs13.

1The Ritchie Centre, Hudson Institute of Medical Research and Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia. 2Department of Immunology and Pathology, Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Alfred Hospital Campus, Monash University, Melbourne, Australia. 3School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia. 4The Ritchie Centre, Hudson Institute of Medical Research, Biotechnology Research Laboratories, Department of Physiology, Monash University, Melbourne, Australia. Magdalena Plebanski, Graeme R. Polglase and Timothy J. Moss jointly supervised this work. Correspondence and requests for materials should be addressed to I.M.I. (email: ishmael.inocencio@monash.edu)
Nanoparticles are characterised as particles of any substance with a diameter less than 100 nm\(^1\). Compared to larger particles, nanoparticles possess a large surface area-to-volume ratio\(^1,2\). Surfaces can be designed specifically to alter their circulation, and biochemical characteristics such as stability, solubility, specificity and bioactivity\(^1,2\). The size of nanoparticles enables specific interactions at molecular, cellular and sub-cellular levels, allowing for delivery to almost every tissue site\(^2\). This technology offers a plethora of potential therapeutic uses of nanoparticles, including their use as vaccine vectors and drug carriers, and for targeted gene therapy\(^1\).

Ostensibly inert nanoparticles can reduce lung inflammation and injury in a proinflammatory environment\(^17,18\) or can induce proinflammatory effects within the lungs\(^19,20\). To date, very few studies have examined the efficacy of nanoparticles for reducing lung inflammation and injury in newborns. There is little known about the response of the preterm lungs to nanoparticle exposure. Such fundamental knowledge is necessary if we are to realise the potential of targeted pulmonary delivery of anti-inflammatory agents using nanoparticles as a new approach to prevention of BPD.

Intra-tracheal administration of PS50G nanoparticles coated in inert glycine resulted in a reduction of lung parenchymal inflammation in an adult mouse asthma model\(^17,21\). We hypothesised that PS50G would have anti-inflammatory properties, like those seen in the adult mouse asthma model, in larger animals. Thus, we aimed to first confirm the anti-inflammatory effect of PS50G in a sheep model of allergic asthma. We also hypothesized PS50G nanoparticles would modulate the proinflammatory response of the preterm lungs to VILI. Therefore, we aimed to determine the effect of prophylactic administration of PS50G on the pulmonary inflammatory response to mechanical ventilation in preterm lambs.

Materials and Methods
Experimental protocols were approved by the relevant Monash University animal ethics committee. All methods were carried out in accordance with the relevant guidelines and regulations, as described by the National Health and Medical Research Council of Australia\(^22\).

Effect of PS50G administration in a sheep asthma model. Female lambs (4–5 months old; \(n = 3\)) sensitized to house dust mite allergen (HDM, *Dermatophagoides pteronyssinus*; CSL Ltd., AUS) were twice administered ‘priming’ airway challenges with HDM at two-week intervals\(^23,24\). Briefly, for airway allergen challenges, sheep were restrained in a harness and HDM (500 µg in 5 ml saline) was delivered into each of the left caudal and right accessory lobes of the lung via the biopsy port of a fiber-optic endoscope\(^23,25\). Bronchoalveolar lavage (BAL) samples were collected (using the endoscope) at 48 h after a second airway challenge to assess baseline airway inflammation\(^23,26\) in the absence of nanoparticle administration.

Twenty-four hours before a third airway allergen challenge two weeks later, PS50G nanoparticles (0.2% beads in 2 ml saline) were administered into the caudal lobe of the left lung using the fibre-optic endoscope as detailed above. Saline (2 ml) was administered into the accessory lobe of the right lung as a control. BAL was collected 48 h after a subsequent HDM challenge, from both the left caudal and right accessory lobes. BAL cells were resuspended in PBS/1%BSA, and cytospots prepared and stained with Wright's solution (Kwik-Diff; Thermo Electron Corp., USA) for differential leukocyte cell counts.
Effect of PS50G administration in ventilated preterm lambs. Pregnant ewes bearing twins or triplets at 125 ± 1 (mean ± SD) days of gestation were anaesthetized by intravenous injection of thiopentone sodium (20 mg/kg). Ewes were intubated and anaesthesia was maintained by inhalational isoflurane (1.5–2.5% in oxygen; Bomac Animal Health, NSW, Australia) delivered via positive pressure ventilation.

Preterm lambs were delivered by caesarean section and randomized to one of three groups: (1) Ventilated with PS50G administration (VENT+NANO), (2) Ventilated without PS50G administration (VENT) and (3) Unventilated Controls (UVC). After clamping and cutting of the umbilical cord, lambs in the UVC group were immediately killed (sodium pentobarbitone; > 100 mg/kg IV) for tissue collection. Lambs in ventilated groups were dried, weighed and placed under an infant warmer (CosyCot, Fisher and Paykel Healthcare, East Tamaki, New Zealand). Ventilation was initiated, and polyvinyl catheters (ID 0.86 mm, OD 1.52 mm, Dural Plastics, Australia) filled with heparinised saline [10 IU/ml heparin (Multiparin Heparin, Fisons Pty Ltd, Australia)] were inserted into an umbilical artery and vein to monitor mean arterial pressure and maintain anaesthesia (Alfaxane 5–15 mg/kg/h; Jurox, East Tamaki, Auckland, New Zealand), respectively. Anaesthesia was maintained for the duration of the experiment.

After delivery of the last lamb the ewe was immediately killed (sodium pentobarbitone; > 100 mg/kg IV) without recovery from anaesthesia. Ventilation of lambs was initiated with warm, humidified air, a peak inspiratory pressure (PIP) of 40 cmH₂O and a positive end-expiratory pressure (PEEP) of 0 cmH₂O (Dräger “Babylog 8000+”, Dräger Medical, Lubeck, Germany), to target a high tidal volume (VT) of (10–12 ml/kg). PIP was adjusted to a maximum of 50 cmH₂O to obtain the target VT. Inspiratory time (Ti) was initially set at 0.4 s but was adjusted during the experiment to achieve the targeted VT. After 15 min lambs were ventilated for a further 1 h and 45 min using volume-guaranteed to deliver VT of 7 ml/kg, with PEEP of 5 cmH₂O, inspiratory time of 0.5 s and expiratory time of 0.5 s. Total ventilation time was 120 min. The fraction of inspired oxygen (FiO₂) was initially set at 40% but was adjusted during the experiment to maintain arterial blood oxygen saturation at 85–95%. This ventilation regimen elicits reproducible lung inflammation and injury in preterm lambs[11,27].

Treatment. Prior to delivery, lambs were randomized to receive either intra-tracheal administration of 3% PS50G in saline (2 ml) (VENT+NANO; n = 6) via the endotracheal tube or no treatment (VENT; n = 5). A single 30-s sustained inflation was given to lambs in the VENT+NANO and VENT groups to help aerate the lungs[28], with the aim of uniformly distributing the nanoparticles.

Arterial blood samples were collected every 5 min for the first 15 min of ventilation, and then every 15 min until the completion of the experiment, for measurement of arterial pH, PCO₂, PO₂ and SO₂ (Fig. 2. 1; ABL30; Radiometer, Copenhagen, Denmark). Expiratory time was adjusted to maintain PaCO₂ between 45–60 mmHg.
Table 1. Primer sequences and polymerase chain reaction conditions.

| Gene     | Species | Genbank Accession# | Forward primer sequence: 5′-3′ | Reverse primer sequence: 5′-3′ | Annealing temperature | cDNA | primer |
|----------|---------|--------------------|-------------------------------|-------------------------------|-----------------------|------|--------|
| 18s      | Rat     | NR_003286          | GTACCGCGCTGAAAGCCCCATT        | CCATCAAATGGTGAGTAGGG          | 60°C                  | 150 ng/μl | 10 ng/μl |
| IL-10    | Sheep   | NM_001009327       | GCTGTACATCTTTGTCGCC           | CTCTCTCACCCTGCACCACC         | 60°C                  | 150 ng/μl | 10 ng/μl |
| IL-8     | Sheep   | NM_001009401       | CCTCAGTAAAGATGCCAATGA         | TGACAGCTAAGCTAGGCCCC         | 60°C                  | 150 ng/μl | 10 ng/μl |
| IL-6     | Sheep   | NM_001009465       | CGATGAGCTTCTGTGTGATG          | CTGTGAGAGGAGGTGGAGAG         | 60°C                  | 150 ng/μl | 10 ng/μl |
| IL-1β    | Sheep   | NM_001009392       | CAGGAAGCTAAGAGCTGAGT          | GAGGAGAGGAGGGAGGGAGG         | 60°C                  | 150 ng/μl | 10 ng/μl |
| CYR61    | Sheep   | DQ239626            | ATGTGCTGAAACACTTTGCTG        | GGGTCACTGTGGAAGTCC         | 60°C                  | 150 ng/μl | 10 ng/μl |
| CTGF     | Sheep   | DQ239672            | TATACGCTCGGCGAGCGCTC          | ACCAATGTTGAGACGCTCA         | 60°C                  | 150 ng/μl | 10 ng/μl |
| EGR1     | Sheep   | DQ239634            | AGGGTCACTGTGGAAGGTC          | GCAGCTGAATCAGGAAGAA         | 60°C                  | 150 ng/μl | 10 ng/μl |

Arterial pressure, carotid blood flow, blood oxygen saturation, heart rate and ventilator and ventilator were monitored and recorded continually throughout the study (Powerlab; ADInstruments, Castle Hill, NSW, Australia).

After ventilation, lambs were harmfully killed (sodium pentobarbitone; >100 mg/kg IV). Tissue samples from all groups were collected immediately (see below).

Lung tissue collection for histological analysis. The lungs were dissected from the chest, and the upper lobe of the right lung was fixed by airway instillation of 10% formalin at 20 cmH2O. After processing, 3 random samples were embedded in paraffin. Ten consecutive 5-μm sections were cut from each sample. Three of the 5-μm sections (each 25 μm apart), were stained with haematoxylin and eosin (H&E) and scored for gross lung injury based on airway wall thickness, epithelial sloughing, and immune and red blood cells within the tissue and airways. Monocytes/macrophage counts were performed on 3 non-overlapping fields of view from 3 lung tissue sections, immunohistochemically stained with an antibody to CD163 (SM2160P, Acris Antibodies, Germany). All histological assessments were made by an investigator blinded to group assignment of the sections.

Lung tissue collection for gene expression analysis. The lower lobe of the right lung was chopped into small pieces, which were immediately frozen in liquid nitrogen. Subsequently, approximately 600 mg of the frozen tissue was weighed and homogenized (Ultra-Turrax T-25; Janke & Kunkel, IKA-Laboritechnik, Germany) for 30 s in 15 ml of lysis buffer (Buffer RLT, Qiagen, Australia) with 150 μl of mercaptoethanol (Sigma-Aldrich, Australia). Total RNA was extracted from homogenized samples (RNeasy Midi Kit, Qiagen) and was reverse-transcribed into cDNA using the cycle threshold (Ct) method of analysis) of the pro-inflammatory cytokines interleukin (IL)-1β, -6 and -8, anti-inflammatory cytokine IL-10 and early injury genes EGR1, CYR61, and CTGF was quantified (primer sequences and PCR conditions are shown in Table 1). The expression of all genes is expressed relative to the mean of the UVC group.

Statistical Analysis. Data are presented as mean ± SEM unless otherwise stated. The change in BAL differential cell counts between the baseline (second) and third HDM challenge (after saline or nanoparticle treatment) were compared by t-tests (ANOVA: Prism 7 for Mac OS X, GraphPad Software, USA). Serial physiological data from preterm lambs were divided into 2 separate epochs: the initial 15 min of ventilation, and the subsequent 1 h 45 min. Each epoch was analysed separately because the method of ventilation was different. Comparisons between groups were made using 2-way repeated measures ANOVA, and the Holm-Sidak post-hoc test was used to compare between groups and/or time-points (Systat Software Inc, USA). Variables measured at single time-points in all 3 groups of lambs (birth weight, umbilical arterial blood gases, tissue measurements) were compared between groups using ANOVA or Kruskal-Wallis test, as appropriate, with Holm-Sidak or Dunn’s multiple comparisons test, respectively (Prism). Histological variables were compared between VENT and VENT+NANO groups using unpaired t-test (Prism).

Results

Effect of nanoparticles on allergic airway inflammation in sheep. The change in airway eosinophil recruitment in response to airway HDM challenge in sensitized sheep was lower in the left caudal lung lobe, where PS50G nanoparticles were administered, than in the saline-administered right accessory lobe (p = 0.026; Fig. 1). Corresponding to the decrease in eosinophil recruitment, there was a greater increase in % BAL macrophages in the PSG50-treated (left caudal) lung lobe compared to the saline-treated (right accessory) lobe (p = 0.08). Changes in the proportions of neutrophils and lymphocytes in BAL did not differ between treatments.

Lamb details. All lambs in the VENT group were male. In the UVC and VENT+NANO groups, 20% and 14% of lambs, respectively, were male. Birth weights, birth order of twins and triplets, and umbilical arterial blood gas measurements were not different between groups (Table 2).
**Table 2.** Characteristics of lambs at birth. Weight and blood gas data are mean ± SEM.

|                        | UVC       | VENT     | VENT+NANO |
|------------------------|-----------|----------|-----------|
| Number                 | 5         | 5        | 6         |
| Sex (% males)          | 20%       | 100%     | 14%       |
| Birth Weight (kg)      | 2.7 ± 0.3 | 3.1 ± 0.2| 2.6 ± 0.1 |
| Lung Weight (g)        | 98.4 ± 13.7 | 108.6 ± 9.1 | 95.8 ± 8.4 |
| Birth Order (Ratio first delivered: second or third delivered) | 1:5       | 3:5      | 3:6       |
| pH                     | 7.23 ± 0.03 | 7.19 ± 0.07 | 7.28 ± 0.01 |
| PaO2 (mmHg)            | 32.9 ± 20.3 | 35.1 ± 9.3 | 25.8 ± 4.2 |
| PaCO2 (mmHg)           | 53.7 ± 16.9 | 67.1 ± 7.4  | 54.9 ± 2.9  |

**Lung inflammation and injury in preterm lambs.** Expression of proinflammatory cytokine and early injury response genes is shown in Fig. 4.

IL-6 mRNA levels were higher in VENT lambs compared to UVC (p = 0.0225), and were higher in VENT+NANO lambs than VENT (p = 0.0323) and UVC (p = 0.0012) groups. IL-8 mRNA levels were higher in VENT and VENT+NANO lambs compared to UVC (p = 0.045 and p = 0.006 respectively). IL-1β mRNA levels were higher in VENT and VENT+NANO lambs compared to UVC but these differences were not statistically significant. IL-10 mRNA levels were lower in VENT (p = 0.0320) and VENT+NANO (p = 0.0269) lambs compared to UVC. CYR61 mRNA levels were higher in VENT+NANO (p = 0.0002) and VENT (p = 0.025) groups than UVC. CTGF mRNA levels were higher in VENT (p = 0.0194) and VENT+NANO (p = 0.0002) lambs than UVC. CTGF mRNA levels were higher in VENT+NANO lambs compared to VENT (p = 0.0004) and UVC lambs (p = 0.0002). EGR1 mRNA levels were higher in the VENT+NANO group compared to both UVC (p = 0.002) and VENT (p = 0.0185).

**Histological analysis.** Indices of histological assessment of lung inflammation and injury are shown in Fig. 5.

Histological scoring of airway wall thickness, inflammatory cell infiltration of the tissue and airways, and epithelial sloughing was greater in the VENT+NANO group than the VENT group (p = 0.05, p < 0.001, p = 0.001 and p = 0.001 respectively). Histological assessments of haemorrhage in the tissue and airways were not different between groups. The number of macrophages/monocytes in fetal lung tissue were higher in the VENT+NANO group than UVC (p = 0.05); numbers in the VENT group were intermediate.

**Discussion and Conclusion**

The initiation of ventilation at birth can cause lung injury, subsequent initiation of an inflammatory cascade and ultimately result in aberrant lung development. Our study demonstrates that nanoparticles, which can reduce inflammation in one context, can exacerbate lung injury and inflammation induced by ventilation in preterm lambs. Increased airway resistance, suggesting acute adverse physical effects of nanoparticle administration, accompanied the exacerbation of lung injury. We confirmed the anti-inflammatory effect of PS50G, demonstrated initially in a mouse model of asthma, by showing similar results in our sheep asthma model. The mouse studies suggest that the uptake of PS50G by dendritic cells (DC) results in a decrease of DC function and numbers. Dendritic cells act to induce a proinflammatory response by processing foreign material and presenting antigens to immune cells. The prevention of downstream effects of DC by PS50G is the likely mechanism of inflammation suppression. Dendritic cells are not present at birth in sheep or humans and are triggered to develop postnataally. Therefore, such an anti-inflammatory action of PS50G is unlikely in the preterm lambs’ lungs. We believe, in the context of our study, an inability to reduce inflammation and the accompanying increased injury may be attributed, at least in part, to the difference between the pulmonary immune systems of the preterm newborn lamb compared to the lungs of adult mice and sheep. We consider that immaturity of the preterm lungs likely limits PS50G clearance by DC.
The principle aim of our investigations in lambs was to determine whether PS50 nanoparticles would have any bioactivity preterm newborns. We reasoned that the relative deficiency of pulmonary antigen presenting cells in preterm newborn lambs would limit the ability of PS50 nanoparticles to act through the same mechanism as they likely do in adult models of asthma. We opted for a high dose, which we considered most likely to have an effect. Having shown a biological effect of PS50 nanoparticles in preterm lambs, albeit a deleterious one,

Figure 3. Respiratory gas exchange in preterm lambs. Blood gases were not different between groups of nanoparticle-treated (n = 6: VENT + NANO; black) or saline-treated (n = 5: VENT; white) preterm lambs. The inspired O₂ content of VENT + NANO lambs was higher than the VENT group (horizontal line shows times at which FiO₂ was different between groups), but the arterial-alveolar O₂ difference and ventilation efficiency index were not different between groups. Data are means ± SEM.

Figure 4. Expression of proinflammatory cytokine and early injury response genes. Messenger RNA (mRNA) levels for proinflammatory cytokines (interleukin (IL)-1β, IL-6 and IL-8) and early injury response genes (cysteine-rich 61 (CYR61), connective tissue growth factor (CTGF), early growth response 1 (EGR1)) were higher, and for anti-inflammatory cytokine IL-10 were lower, in ventilated lambs treated with saline (VENT, white circles) or nanoparticles (VENT + NANO, black circles) than in unventilated controls (UVC, grey circles). Levels of mRNA for IL-6, CTGF and EGR1 were higher in the VENT + NANO group that the VENT group. Data are expressed relative to the mean of the UVC group.

The principle aim of our investigations in lambs was to determine whether PS50 nanoparticles would have any bioactivity preterm newborns. We reasoned that the relative deficiency of pulmonary antigen presenting cells in preterm newborn lambs would limit the ability of PS50G nanoparticles to act through the same mechanism as they likely do in adult models of asthma. We opted for a high dose, which we considered most likely to have an effect. Having shown a biological effect of PS50G nanoparticles in preterm lambs, albeit a deleterious one,
bioactivity is confirmed in this context. Future experiments are now justified to determine the effects of lower doses. Our work clearly shows caution is required around the use of nanoparticles in perinatal subjects.

Our study in preterm lambs used a ventilation strategy known to result in lung injury and inflammation, with initial delivery of high tidal volumes\(^{11,33}\). Stretch-induced injury of cells in the airways and lung parenchyma is a major contributor to neonatal lung injury and the pathogenesis of BPD\(^7\). In our experiment the tidal volumes delivered to ventilated lambs were not different between PS50G-treated and untreated groups. Thus, differences in stretch-induced injury are unlikely to be responsible for the differences in lung injury and inflammation between groups.

Our groups of preterm lambs had different proportions of male and female subjects. We are unaware of data showing differences in lung injury responses to ventilation in male and female preterm newborns, over a time frame like that in our study. De Matteo et al. recently showed no sex difference in lung injury of preterm lambs, as indicated by the presence of protein in bronchoalveolar lavage fluid 8 hours after birth\(^{34}\), and we showed that the cardiopulmonary hemodynamic transition at birth is not different between male and female preterm lambs\(^35\). Thus, the differences we observed between groups are unlikely confounded by sex of the subjects.

Although peak inspiratory pressures and tidal volumes were equivalent between groups, we observed evidence of impaired airway function in preterm lambs treated with PS50G. These lambs required longer inspiratory times to generate tidal volume, resulting in greater mean airway pressures (even though PIP was equivalent), consistent with the measured increase in airway resistance in these lambs. We consider this increase in airway resistance is likely the result of small airway blockage by the nanoparticles at the high dosage used in this study.

We believe the histological evidence of lung injury observed in our study is a direct consequence of PS50G nanoparticles in the lungs, rather than the changes in lung function we observed. Pulmonary exposure to
particulate matter results in oxidative stress, resulting in subsequent promotion of a pro-inflammatory response, thus contributing toward chronic lung disease. It is known that nanoparticles can induce greater responses than larger micron-sized particles.

We observe an up-regulation of pro-inflammatory mediators in response to PS50G administration in preterm lambs. However, the 2-h timeframe of our experiment is too short for the increased inflammatory cascade to result in substantial morphological changes to the lung tissue. Mechanical ventilation of preterm lambs is known to increase pulmonary monocyte recruitment and differentiation of these cells to pulmonary macrophages. PS50G nanoparticles more-than-doubled pulmonary monocyte/macrophage recruitment in preterm lambs but this increase was not statistically significant. We consider that differences in the proportions of monocytes/macrophages in PS50-treated versus untreated lung lobes in asthmatic adult sheep are likely the consequence of the reduction in eosinophils. We did not conduct total cell counts on bronchoalveolar lavage fluid samples from these sheep, so we cannot determine total monocyte/macrophage numbers.

We believe the increase in histological signs of lung injury seen in the PS50G group is due to an increase in mechanical stress caused by PS50G. Atelectrauma may have occurred from potential interference with surfactant resulting in an increase in surface tension. Furthermore, blockage within the airways may have resulted in excessive volume delivered to other lung regions, thereby resulting in volutrauma and barotrauma. We believe that high dose of PS50G further increased physical injury resultant from injurious ventilation, resulting in the observed changes to lung morphology. Our principle aim was to determine whether PS50 nanoparticles would have any bioactivity in ventilated preterm lambs. We reasoned that the relative deficiency of pulmonary antigen presenting cells in preterm newborn lambs would limit the ability of PS50G nanoparticles to act through the same mechanism as they likely do in adult models of asthma. We opted for a high dose, which we considered most likely to have an effect. Having shown a biological effect of PS50G nanoparticles in preterm lambs, albeit a deleterious one, bioactivity is confirmed in this context. Future experiments are now justified to determine the effects of lower doses. Our work clearly shows caution is required around the use of nanoparticles in perinatal subjects.

There are a number of potential approaches to inhibit pulmonary inflammation and injury, in addition to use of either inert or drug-conjugated nanoparticles. Corticosteroids have long been used to inhibit pulmonary inflammation, and have benefit in reducing lung inflammation and chronic lung disease in preterm infants; the challenge is identification of an effective but safe dose of these powerful anti-inflammatory agents, which have profound effects on development. It is possible that inhaled corticosteroids may have utility in this respect. More precise anti-inflammatory therapies may also be able to reduce lung inflammation in preterm neonates. The TNF antagonist Etanercept and the interleukin-1 receptor antagonist Anakinra reduce lung inflammation and prevent consequent abnormal lung development in mouse models of bronchopulmonary dysplasia. Anti-interleukin 4Rα reduces inflammation in a mouse asthma model. Other anti-inflammatory agents, which target the inflammatory cascade via immunomodulatory mechanisms.

Conclusions
Our study shows that high dose of PS50G nanoparticles can exacerbate newborn lung inflammation and injury in response to mechanical ventilation. This is despite a demonstrated anti-inflammatory effect of PS50G nanoparticles in mouse and sheep models of allergic asthma. Our study suggests a cautious approach is required to the introduction of nanoparticle-based therapies in newborns.

References
1. ES, R. Pre-term births on the rise. Nature. 485, 20 (2012).
2. Blencowe, H. et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 379, 2162–72 (2012).
3. Moss, T. J. M. Respiratory consequences of preterm birth. in Clinical and Experimental Pharmacology and Physiology. 33, 280–284 (2006).
4. Li, Z., Zeki, R., Hilder, L. & Sullivan, E. A. (ed. A.N.E.P.A.S. Unit.) (Canberra, Australia; 2011).
5. Schmolzer, G. M. et al. Airway obstruction and gas leak during mask ventilation of preterm infants in the delivery room. Arch. Dis. Child. Fetal Neonatal Ed. 96, F254–F257 (2011).
6. Hillman, N. H. et al. Airway injury from initiating ventilation in preterm sheep. Pediatr. Res. 67, 60–65 (2010).
7. Jobe, A. H. et al. Injury and inflammation from resuscitation of the preterm infant. Neonatology 94, 190–196 (2008).
8. Djokic, L. J. et al. Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs. Pediatr. Res. 42, 348–355 (1997).
9. Kinsella, J. P., Greenough, A. & Abman, S. H. Bronchopulmonary dysplasia. Lancet 367, 1421–1431 (2006).
10. Jobe, A. H. The new bronchopulmonary dysplasia. Curr Opin Pediatr. 23, 167–172 (2011).
11. Wallace, M. J. et al. Early biomarkers and potential mediators of ventilation-induced lung injury in very preterm lambs. Respir. Res. 10, 19 (2009).
12. Hillman, N. H. et al. Inflammation and lung maturation from stretch injury in preterm fetal sheep. Am. J. Physiol. Lung Cell. Mol. Physiol. 300, L232–241 (2011).
13. De Jong, W. H. & Borm, P. J. a. Drug delivery and nanoparticles-applications and hazards. Int J. Nanomedicine. 3, 133–149 (2008).
14. Mohamud, R. et al. The effects of engineered nanoparticles on pulmonary immune homeostasis. Drug Metab. Rev. 46, 176–190 (2014).
15. Van Rijt, S. H., Bein, T. & Meiners, S. Medical nanoparticles for next generation drug delivery to the lungs. European Respiratory Journal 44, 765–774 (2014).
16. Azarni, S., Roa, W. H. & Lobenberg, R. Targeted delivery of nanoparticles for the treatment of lung diseases. Advanced Drug Delivery Reviews 60, 863–875 (2008).
17. Hardy, C. L. et al. Inert 50-nm Polystyrene Nanoparticles that Modify Pulmonary Dendritic Cell Function and Inhibit Allergic Airway Inflammation. J. Immunol. 188, 1431–1441 (2012).
18. Duivenvoorden, R. et al. A statin-reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat. Commun. 5 (2014).
19. Cho, W.-S. et al. Progressive severe lung injury by zinc oxide nanoparticles: the role of Zn2+ dissolution inside lysosomes. Part. Fibre Toxicol. 8, 27 (2011).
20. Chen, H.-W. W. et al. Titanium dioxide nanoparticles induce emphysema-like lung injury in mice. FASEB J. 20, 2393–5 (2006).
21. Hardy, C.-L. et al. Differential uptake of Nanoparticles and Microparticles by Pulmonary APC Subsets induces Discrete Immunological Imprints. J. Immunol. 191, 5278–5290 (2013).
22. Perry, M. Revised Australian Code of Practice for the care and use of animals for scientific purposes. Australian veterinary journal 76, (2013).
23. Bischof, R. J., Snibson, K., Shaw, R. & Meeusen, E. N. T. Induction of allergic inflammation in the lungs of sensitized sheep after local challenge with house dust mite. Clin. Exp. Allergy 33, 367–375 (2003).
24. Larivi, R., Piedrafitta, D., Nguyen, G. & Bischof, R. J. Dynamics of IL-4 and IL-13 expression in the airways of sheep following allergen challenge. BMC Pulm. Med. 1–11 doi:10.1186/1471-2466-11-9 (2011).
25. Meesuen, E. N., Snibson, K. J., Hirst, S. J. & Bischof, R. J. Sheep as a model species for the study and treatment of human asthma and other respiratory diseases. Drug Discovery Today: Disease Models. 6, 101–106 (2010).
26. Bischof, R. J., Snibson, K. J., Van Den Velden, J. & Meesuen, E. N. Immune response to allergens in sheep sensitized to house dust mite. J. Inflamm. (Lond). 5, 16 (2008).
27. Polglase, G. R. et al. Positive end-expiratory pressure and tidal volume during initial ventilation of preterm lambs. Pediatr. Res. 64, 517–522 (2008).
28. Te Pas, A. B. et al. Establishing functional residual capacity at birth: The effect of sustained inflation and positive end-expiratory pressure in a preterm rabbit model. Pediatr. Res. 65, 337–541 (2009).
29. Matute-Bello, G. et al. An official American thoracic society workshop report: Features and measurements of experimental acute lung injury in animals. in American Journal of Respiratory Cell and Molecular Biology. 44, 725–738 (2011).
30. Howard, C. J., Charleston, B., Stephens, S. a., Sopp, P. & Hope, J. C. The role of dendritic cells in shaping the immune response. Anim. Heal. Res. Rev. 5, 191–195 (2004).
31. Kopf, M., Schneider, C. & Nobs, S. P. The development and function of lung-resident macrophages and dendritic cells. Nat Immunol 16, 36–44 (2015).
32. Halleraker, M., Press, C. M.L. & Landsverk, T. Development and cell phenotypes in primary follicles of foetal sheep lymph nodes. Cell Tissue Res. 275, 51–62 (1994).
33. Hillman, N. H. et al. Brief, large tidal volume ventilation initiates lung injury and a systemic response in fetal sheep. Am. J. Respir. Crit. Care Med. 176, 573–581 (2007).
34. De Matteo, R., Ishak, N., Hanita, T., Harding, R. & Soto, F. Respiratory adaptation and surfactant composition of unanesthetized male and female lambs differ for up to 8 h after preterm birth. Pediatr. Res. 79, 13–21 (2016).
35. Polglase, G. R. et al. The cardiopulmonary haemodynamic transition at birth is not different between male and female preterm lambs. Reprod. Fertil. Dev. 24, 510–516 (2012).
36. Byrne, J. D. & Baugh, J. A. The significance of nanoparticles in particle-induced pulmonary fibrosis. Megill Journal of Medicine 11, 43–50 (2008).
37. Anderson, J. O., Thundiyil, J. G. & Stolbach, A. Clearing the air: a review of the effects of particulate matter air pollution on human health. Journal of Medical Toxicology 8, 166–175 (2012).
38. Ahmad, J. et al. Nanotechnology-based inhalation treatments for lung cancer: State of the art. Nanotechnology, Science and Applications 8, 55–66 (2015).
39. El Sherbiny, M. et al. Differential uptake of Nanoparticles and Microparticles by Pulmonary APC Subsets induces Discrete Immunological Imprints. J. Immunol. 191, 5278–5290 (2013).
40. Goel, A., Baboota, S., Sahni, J. K. & Ali, J. Exploring targeted pulmonary delivery for treatment of lung cancer. Int. J. Pharm. Investig. 3, 8–14 (2013).
41. Halwani, R. et al. A novel anti-IL4Rα nanoparticle efficiently controls lung inflammation during asthma. Exp. Mol. Med. 48, e262 (2016).
42. Gupta, S., Prasanth, K., Chen, C.-M. & Yeh, T. F. Postnatal Corticosteroids for Prevention and Treatment of Chronic Lung Disease in the preterm Newborn. Int. J. Pediatr. 2012, 1–12 (2012).
43. Aziz, K. Postnatal steroids for chronic lung disease - A lesson learned. Paediatrics and Child Health. 7, 9–10 (2002).
44. Vyas, J. & Kotecha, S. Effects of antenatal and postnatal corticosteroids on the preterm lung. Arch. Dis. Child. Fetal Neonatal Ed. 77, F147–50 (1997).
45. Oncel, M. Y. et al. Beneficial Effect of etanercept on hyperoxic lung injury model in neonatal Rats. J. Investig. Surg. 26 (2019).
46. Nold, M. F. et al. IL-1 receptor antagonist prevents murine bronchopulmonary dysplasia induced by perinatal inflammation and hyperoxia. Proc. Natl. Acad. Sci. 110, 14384–14389 (2013).
47. Chen, X. et al. Metformin attenuates hyperoxia-induced lung injury in neonatal rats by reducing the inflammatory response. Am. J. Physiol. - Lung Cell. Mol. Physiol. 309, L262–270 (2015).
48. Mansur, A. et al. Impact of statin therapy on mortality in patients with sepsis-associated acute respiratory distress syndrome (ARDS) depends on ARDS severity: a prospective observational cohort study. BMC Med. 13, 128 (2015).
49. Vosdoganes, P., Lim, R., Moss, T. J. M. & Wallace, E. M. Cell therapy: a novel treatment approach for bronchopulmonary dysplasia. Pediatr. 130, 727–37 (2012).

Acknowledgements

The authors gratefully acknowledge the technical assistance of all members of the Perinatal Transition and Perinatal Inflammation research groups at the Ritchie Centre. This research was supported by the National Health and Medical Research Council (NHMRC) of Australia through grants to the Preterm Infants Centre of Research Excellence (1057514), NHMRC Research Fellowships (GRF: 1105526 and TJM: 1043294), RMIT Vice Chancellor's Senior Research Fellowship (MT) and the Victorian Government's Operational Infrastructure Support Program.

Author Contributions

I.I. wrote the first draft of the manuscript. T.M. prepared the Figures. R.B. conducted experiments on PS50G effect in ashtmatic sheep. S.X. and M.P. provided PS50G and contributed to experimental design. V.Z., V.N., T.L., D.L., J.B. performed experiments. M.T., G.P. and T.M. contributed to experimental design for the preterm lamb experiments. I.I., R.B., M.T., M.P., S.X., G.P. and T.M. contributed to analysis and interpretation of data. All authors reviewed, revised and approved the manuscript.
Additional Information

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017